Investment Analysts’ Updated EPS Estimates for March 18th (AGEN, AKYA, ALGN, ALT, ATNM, BLTE, BTM, CANF, CCB, COYA)

Investment Analysts’ updated eps estimates for Tuesday, March 18th:

Agenus (NASDAQ:AGEN) had its neutral rating reaffirmed by analysts at HC Wainwright.

Akoya Biosciences (NASDAQ:AKYA) had its overweight rating reaffirmed by analysts at Stephens. The firm currently has a $3.50 price target on the stock.

Align Technology (NASDAQ:ALGN) had its overweight rating reiterated by analysts at Piper Sandler. Piper Sandler currently has a $235.00 target price on the stock, down from their previous target price of $270.00.

Altimmune (NASDAQ:ALT) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $12.00 price target on the stock.

Actinium Pharmaceuticals (NYSE:ATNM) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $4.00 target price on the stock.

Belite Bio (NASDAQ:BLTE) had its overweight rating reiterated by analysts at Cantor Fitzgerald.

Belite Bio (NASDAQ:BLTE) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $100.00 target price on the stock.

Bitcoin Depot (NASDAQ:BTM) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $4.00 target price on the stock.

Can-Fite BioPharma (NYSE:CANF) had its buy rating reiterated by analysts at D. Boral Capital. The firm currently has a $10.00 target price on the stock.

Coastal Financial (NASDAQ:CCB) had its overweight rating reissued by analysts at Stephens. The firm currently has a $100.00 target price on the stock.

Coya Therapeutics (NASDAQ:COYA) had its buy rating reaffirmed by analysts at D. Boral Capital. D. Boral Capital currently has a $18.00 price target on the stock.

Electra Battery Materials (NASDAQ:ELBM) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $2.40 price target on the stock.

Entera Bio (NASDAQ:ENTX) had its buy rating reissued by analysts at HC Wainwright. They currently have a $10.00 price target on the stock.

Eos Energy Enterprises (NASDAQ:EOSE) had its buy rating reiterated by analysts at Guggenheim. Guggenheim currently has a $7.00 target price on the stock.

Ferguson (NASDAQ:FERG) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a $189.00 target price on the stock.

FibroGen (NASDAQ:FGEN) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $10.00 target price on the stock.

The GEO Group (NYSE:GEO) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $46.00 target price on the stock.

Guess? (NYSE:GES) had its market perform rating reissued by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $18.00 price target on the stock.

Globus Medical (NYSE:GMED) had its hold rating reiterated by analysts at Needham & Company LLC.

Gossamer Bio (NASDAQ:GOSS) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $10.00 target price on the stock.

Harrow (NASDAQ:HROW) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $57.00 price target on the stock.

MiNK Therapeutics (NASDAQ:INKT) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $35.00 price target on the stock.

KULR Technology Group (NYSEAMERICAN:KULR) had its buy rating reissued by analysts at Benchmark Co.. They currently have a $5.00 price target on the stock.

Leslie’s (NASDAQ:LESL) had its market perform rating reaffirmed by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $3.00 target price on the stock.

Spectral AI (NASDAQ:MDAI) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $3.50 target price on the stock.

Mereo BioPharma Group (NASDAQ:MREO) had its overweight rating reiterated by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $7.00 target price on the stock.

Merus (NASDAQ:MRUS) had its buy rating reiterated by analysts at Guggenheim. The firm currently has a $109.00 target price on the stock.

Pfizer (NYSE:PFE) had its buy rating reissued by analysts at Guggenheim.

Pliant Therapeutics (NASDAQ:PLRX) had its neutral rating reiterated by analysts at HC Wainwright.

Roblox (NYSE:RBLX) had its buy rating reissued by analysts at Benchmark Co.. Benchmark Co. currently has a $71.00 price target on the stock.

AVITA Medical (NASDAQ:RCEL) had its buy rating reaffirmed by analysts at D. Boral Capital. D. Boral Capital currently has a $22.00 target price on the stock.

Rivian Automotive (NASDAQ:RIVN) had its buy rating reiterated by analysts at Benchmark Co.. They currently have a $18.00 price target on the stock.

Sana Biotechnology (NASDAQ:SANA) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $11.00 price target on the stock.

Sangamo Therapeutics (NASDAQ:SGMO) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. They currently have a $2.00 price target on the stock.

Sable Offshore (NYSE:SOC) had its sell rating reiterated by analysts at BWS Financial. BWS Financial currently has a $6.00 price target on the stock.

Sarepta Therapeutics (NASDAQ:SRPT) had its overweight rating reaffirmed by analysts at Cantor Fitzgerald. Cantor Fitzgerald currently has a $163.00 target price on the stock.

Sarepta Therapeutics (NASDAQ:SRPT) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $202.00 price target on the stock.

STAAR Surgical (NASDAQ:STAA) had its equal weight rating reiterated by analysts at Stephens. The firm currently has a $17.00 target price on the stock.

Stoke Therapeutics (NASDAQ:STOK) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $22.00 price target on the stock.

SolarBank (NASDAQ:SUUN) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $6.00 price target on the stock.

Townsquare Media (NYSE:TSQ) had its outperform rating reiterated by analysts at Barrington Research. The firm currently has a $15.00 target price on the stock.